Side-by-side · Research reference

CrystagenvsProstamax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BAnimal-MechanisticHUMAN-REVIEWED11/38 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

Prostamax

Khavinson Bioregulator · Tissue-Specific Peptide

0.05 ng/mLActive concentrationZakutskiĭ 2006

2.5×SCE frequency increaseDzhokhadze 2012

4 AAPeptide length

SQ · Protocol per Khavinson tradition

01Mechanism of Action

Parameter

Crystagen

Prostamax

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Chromatin in prostatic cells — pericentromeric heterochromatin regions

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012 Zakutskiĭ 2006

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

—

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

Prostamax

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

—

Evidence basis

Animal / mechanistic

Animal / organotypic cultureZakutskiĭ 2006 Dzhokhadze 2012

No randomized controlled trials in humans.

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

—

Duration

Unknown — chronic administration presumed in animal models

Not specified

Khavinson protocols typically 10–20 days per cycle; no long-term safety data.

Half-life

Not reported

—

Effective concentration (in vitro)

—

0.05 ng/mLZakutskiĭ 2006

Organotypic culture model; demonstrated tissue-specific stimulation.

Human clinical dose

—

Not established

No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).

Age groups studied

—

Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006 Dzhokhadze 2012

04Side Effects & Safety

Parameter

Crystagen

Prostamax

Published adverse events

None reported in available animal literature

None reported in available literature

Human safety data

Absent — no controlled human trials identified

Absent — no published Phase 1/2/3 trials

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Genotoxicity signals

—

Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications

Metal ion interactions

—

Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

Prostamax

·Active prostate malignancy — epigenetic modulation effects unknown in cancer

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

Prostamax

·History of prostate cancer — theoretical concern re: transcriptional activation
·Undiagnosed prostatic nodules or elevated PSA

05Administration Protocol

Parameter

Crystagen

Prostamax

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).

5. Note

—

All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

Prostamax

— no documented stacks